Marshall Wace, LLP Novo Cure LTD Transaction History
Marshall Wace, LLP
- $78.4 Billion
- Q4 2024
A detailed history of Marshall Wace, LLP transactions in Novo Cure LTD stock. As of the latest transaction made, Marshall Wace, LLP holds 270,952 shares of NVCR stock, worth $4.99 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
270,952
Previous 779,670
65.25%
Holding current value
$4.99 Million
Previous $12.2 Million
33.74%
% of portfolio
0.01%
Previous 0.02%
Shares
15 transactions
Others Institutions Holding NVCR
# of Institutions
290Shares Held
75.6MCall Options Held
1.77MPut Options Held
538K-
Black Rock Inc. New York, NY12.1MShares$223 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$217 Million0.01% of portfolio
-
Capital International Investors Los Angeles, CA8.87MShares$163 Million0.05% of portfolio
-
Capital World Investors Los Angeles, CA4.82MShares$88.7 Million0.02% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.74MShares$50.4 Million5.68% of portfolio
About NovoCure Ltd
- Ticker NVCR
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 104,950,000
- Market Cap $1.93B
- Description
- NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...